


SYNTHESIS OF TWO RIGID DIACYLGLYCEROL ANALOGUES HAVING A PERHYDRO FURO[3,2-*b*]FURAN BIS- γ -BUTYROLACTONE SKELETON. 3.

Jeewoo Lee¹, Victor E. Marquez^{1*}, Afshin Bahador,² Marcelo G. Kazanietz,² and Peter M. Blumberg²
¹Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, and ²Molecular Mechanisms of Tumor Promotion Section, Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, NIH, Bethesda, Maryland 20892 (USA)

Abstract: The stereoselective synthesis of two new bis- γ -butyrolactones starting from 1,2:5,6-di-O-isopropylidene- α -D-allofuranose was completed in 22 steps. One of the isomers (**3a**) showed very good binding affinity towards protein kinase C.


In the preceding communication¹ we examined the protein kinase C (PK-C) binding affinity of two isomeric bis- γ -butyrolactones (**2a,b**) that were synthesized as rigid diacylglycerol (DAG) analogues. These compounds were conceived to restrict the freedom of rotation about the O-acyl bond by incorporating the acyl moiety as part of a second lactone ring (Scheme 1a). In performing this connection, the R₁ and R₂ groups were integrated into a single long alkyl R substituent. Despite the good PK-C binding affinity displayed by the progenitor monolactones **1**,^{2,3} in which either R₁ or R₂ represent long alkyl chains, neither resulting bicyclic structure, **2a** or **2b**, showed good binding affinity towards PK-C.¹ In this communication, we wish to report the synthesis and PK-C binding affinity of a new set of bis- γ -butyrolactones (**3a,b**) that can be envisioned as resulting from a different mode of restricting the freedom of rotation of the acyl chain (Scheme 1b).

Scheme 1




Retrosynthetic analysis of these targets suggested the use of either 1,2:5,6-di-O-isopropylidene- α -D-glucufuranose, or the isomeric 1,2:5,6-di-O-isopropylidene- α -D-allofuranose (**4**) as chiral building blocks.

For reasons to be discussed later, the allofuranose precursor was preferred. Building of the second lactone ring was envisaged to proceed after appropriate transformations at both C-3 and C-4 positions of the sugar (steps *e* and *d*). Later, for the construction of the alkyl chain R, two options were considered: 1) alkylation of the preformed bicyclic structure (step *a*) or 2) introduction of the alkyl group at an early stage of the synthesis (step *e*, R = C_nH_{2n+1}), followed by lactonization (steps *d* and *b*, R = C_nH_{2n+1}). Although the first approach seemed very attractive, alkylation of the bis- γ -butyrolactone system (LDA, THF, C_nH_{2n+1}I, -78 °C) failed due to facile β -elimination of the β -alkoxylactone. The second alternative, although somewhat cumbersome, worked well (Scheme 2). The selection of this route, which required an early alkylation step, convinced us to choose the allofuranose precursor 4 which offered no steric encumbrance on the β -face.



The starting 1,2:5,6-di-O-isopropylidene- α -D-allofuranose (4) was prepared from the corresponding α -D-glucofuranose derivative according to published methodology.⁴ The next three steps: benzylation of the 3-hydroxyl group, opening of the 5,6-O-isopropylidene ring, and selective tritylation of the resulting primary 6-hydroxyl group were performed in a combined yield of 65%. Oxidation of the free secondary alcohol in 5 with pyridinium chlorochromate (PCC), followed by Grignard addition of C₁₂H₂₅MgBr, produced the expected mixture of diastereoisomers (6a,b). Throughout the ensuing steps isomers were not separated until the end of the synthesis. Radical deoxygenation of the newly generated tertiary alcohol proceeded uneventfully via the xanthate intermediate to give 7a,b. Removal of the O-benzyl group with Na in liquid ammonia cleaved also the trityl group to give an intermediate which was then selectively protected as a *t*-butyldimethylsilyl ether derivative (8a,b). Oxidation of 8a,b with pyridinium dichromate (PDC) was followed by a Wittig reaction to form the methylene compound 9a,b which was regiospecifically cis-hydroxylated with OsO₄ from the less hindered β -face. The resulting diol intermediate was then selectively monobenzylated via the 3,5-O-(dibutylstannylene) derivative to give the advanced intermediate 10a,b. At this point, lactonization was achieved, in one step, via oxidation of the unmasked primary alcohol. Most

Scheme 2



Reagents and Conditions: a. BnBr, NaH, Bu₄NI, THF, rt 2h. b. 0.06 N HCl/MeOH, 55 °C 2h. c. TrCl, pyridine/DMF, rt 12 h (65% steps a-c). d. PCC, 4Å mol. sieves, rt 1.5 h (98%). e. C₁₂H₂₅MgBr, ether, -10 °C → rt (85%). f. NaH, CS₂, MeI, DMF, 80 °C (75%). g. Bu₃SnH/azobis(isobutyronitrile), toluene, Δ 1h (82%). h. Na, liq.NH₃/THF (90%). i. Me₃CPh₂SiCl, NEt₃, DMAP, CH₂Cl₂, rt 12 h (95%). j. PDC, AcOH 4Å mol. sieves, CH₂Cl₂, rt 1h (98%). k. Me(PPh₃)Br, BuLi, THF, -10 °C → rt (84%). l. OsO₄, 4-Methylmorpholine *N*-oxide, aq. acetone, rt 12 h (92%). m. i. (Bu₃Sn)₂O, toluene, Δ 4 h. ii. BnBr, Bu₄NBr, 80 °C 24 h (98%). n. Bu₄NF, THF, rt 0.5 h (98%). o. PCC, 4Å mol sieves, CH₂Cl₂, rt 1h (96%). p. H⁺-Resin, MeOH, Δ 12 h (95%). q. NaH, CS₂, MeI, THF, rt (93%). r. Bu₃SnH/azobis(isobutyronitrile), toluene, Δ 1 h (66%). s. HCl, AcOH-H₂O-THF, 90 °C 4 h (96%). t. PCC, CH₂Cl₂, rt 1 h (98%). u. H₂, Pd/C, MeOH, rt 2 h (94%).

likely, the transiently formed cyclic hemiacetal was immediately oxidized *in situ* to the lactone 11a,b. To complete the synthesis, removal of the acetonide group, followed by a second radical deoxygenation gave 12a,b. Hydrolysis of this methyl glycoside and oxidation to the corresponding lactol gave a mixture of the desired bis- γ -butyrolactone 13a,b. Finally, removal of the O-benzyl protection and chromatographic separation of the isomers (silica gel, hexane:ethyl acetate, 1:1) gave the two targets 3a and 3b.^{5,6} The obtained ratio of 3b/3a = 3 reflects the kind of selectivity obtained during the Grignard alkylation step performed earlier in the synthesis. As before, characterization of each isomer was possible by examining the value of the $J_{3,3a}$ coupling constant.^{5,6}

Evaluation of these compounds for their ability to inhibit [20-³H]phorbol-12,13-dibutyrate binding to PK-C indicated that isomer 3a was an excellent competitive inhibitor with a K_i of 6.1 μ M, while the corresponding isomer 3b had an ID_{50} of greater than 100 μ M. Compound 3a is the most potent inhibitor of all of the bis- γ -butyrolactones examined to date in our laboratory.

References and Notes

1. Lee, J.; Marquez, V. E.; Lewin, N. E.; Blumberg, P. M. *Tetrahedron Lett.* previous communication.
2. Teng, K.; Marquez, V. E.; Milne, G. W. A.; Barchi, Jr., J. J.; Kazanietz, M. G.; Lewin, N. E.; Blumberg, P. M.; Abushanab, E. *J. Am. Chem. Soc.* **1992**, *114*, 1059.
3. Lee, J.; Marquez, V. E.; Lewin, N. E.; Kazanietz, M. G.; Bahador, A.; Blumberg, P. M. *Bioorg. Med. Chem. Lett.* in press.
4. Sowa, W.; Thomas, H. S. *Can. J. Chem.* **1966**, *44*, 836.
5. Compound 3a, mp 84.5 °C; $[\alpha]_D^{24} +68.6^\circ$ (c 0.22, CHCl₃); IR (KBr) 3496 (OH) and 1773 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 5.06 (d, $J_{3,3a} = 5.7$ Hz, 1 H, H_{3a}), 4.03 (dd, $J_{gem} = 11.9$, $J_{H,OH} = 4.2$ Hz, 1 H, CHHOH), 3.82 (dd, $J_{gem} = 11.9$, $J_{H,OH} = 4.8$ Hz, CHHOH), 2.97 (m, 1 H, H₃), 2.87 (d, $J_{gem} = 18.6$ Hz, 1 H, H_{6a}), 2.74 (d, $J = 18.6$ Hz, 1 H, H_{6b}), 2.30 (br s, 1 H, OH), 1.15-1.95 (m, 22 H, CH₂'s), 0.86 (distorted triplet, 3 H); ¹³C NMR δ 175.87, 172.25, 87.64, 81.90, 63.82, 45.30, 36.50, 31.90, 29.69, 29.64, 29.61, 29.53, 29.35, 27.59, 24.91, 22.68, 14.11; FAB MS m/z (rel intensity) 341 (MH⁺, 100). Anal. Calcd for C₁₉H₃₂O₅: C, 67.03; H, 9.48. Found: C, 66.50; H, 9.44.
6. Compound 3b, mp 91 °C; $[\alpha]_D^{24} +22.7^\circ$ (c 0.65, CHCl₃); IR (KBr) 3447 (OH) and 1774 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ 4.85 (d, $J_{3,3a} = 1.6$ Hz, 1 H, H_{3a}), 3.96 (dd, $J_{gem} = 11.9$, $J_{H,OH} = 5.0$ Hz, 1 H, CHHOH), 3.77 (dd, $J_{gem} = 11.9$, $J_{H,OH} = 6.0$ Hz, CHHOH), 2.91 (d, $J_{gem} = 19.0$ Hz, 1 H, H_{6a}), 2.78 (d, $J = 19.0$ Hz, 1 H, H_{6b}), 2.81 (m, 1 H, H₃), 2.12 (br s, 1 H, OH), 1.15-1.95 (m, 22 H, CH₂'s), 0.86 (distorted triplet, 3 H); ¹³C NMR δ 175.99, 172.47, 87.57, 84.36, 64.32, 47.93, 36.25, 31.89, 29.61, 29.57, 29.49, 29.32, 28.98, 28.79, 27.57, 22.67, 14.09; FAB MS m/z (rel intensity) 341 (MH⁺, 100). Anal. Calcd for C₁₉H₃₂O₅: C, 67.03; H, 9.48. Found: C, 66.39; H, 9.39.

(Received in USA 26 March 1993; accepted 12 May 1993)